ERYtech Pharma Completes the Enrollment of Patients in Its Phase I Clinical Trial in Pancreatic Cancer
Published: Jun 27, 2011
LYON, France & PHILADELPHIA--(BUSINESS WIRE)-- ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma. The first results in this study demonstrated that Graspa® was active, with a safety profile that was satisfactory for patients in last-line therapy. On the back of this success, ERYTECH is expecting to forge ahead with the clinical development of Graspa® for the treatment of pancreatic cancer in “responder” patients.